RGNT
REGENTIS BIOMATERIALS LTD.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Jun 15 Regentis Biomaterials withdrew its Form F-1 registration statement f…
- R Jul 14 The SEC declared Regentis Biomaterials' F-1 registration statement e…
- R Jul 15 Regentis received European Notified Body approval for a next-generat…
- X Jul 31 Short interest falls 53.9% to 37.1K
- X Aug 14 Short interest falls 77.9% to 8.2K
- X Aug 31 Short interest jumps 64.4% to 13.5K
- X Sep 15 Short interest falls 51.0% to 6.6K
- X Sep 30 Short interest falls 42.4% to 3.8K
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q2 2026: 1 added (0 new), 0 trimmed or exited.
- TrendDOWNTREND
31% below its 50-day average. New closing low $1.28 on Oct 23.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | ADD | $1.5K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Price is below the lowest target. Median implies +681%.Targets as of Oct 27, 2026.
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Jul 9, 2026 | Cohen-Arazi Efraim Director | AWARD | 24,826 sh |
| Jul 9, 2026 | GELLER EHUD Chief Executive Officer | AWARD | 31,250 sh |
| Jul 9, 2026 | Dykan Jeff Director | AWARD | 12,500 sh |
| Jul 9, 2026 | Dykan Jeff Director | AWARD | 24,826 sh |
| Jul 9, 2026 | Valentine Keith Director | AWARD | 24,826 sh |
| Jul 9, 2026 | Ben-Elazar Pini Director | AWARD | 24,826 sh |
| Jul 9, 2026 | Ben-Elazar Pini Director | AWARD | 8,313 sh |
| Jul 9, 2026 | Alpert Susan PHD MD Director | AWARD | 24,826 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | -$0.68 | -$0.68–-$0.68 | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
8 filings · 2 bullish · 1 bearish · 1 mixed · 4 neutral- NEUTRAL 6-KOct 13, 2026
Regentis Biomaterials reported strong surgeon interest in its GelrinC hydrogel implant at the 8th…
This is a routine conference attendance press release with no new material data. Monitor the U.S. FDA pivotal trial enrollment completion and any subsequent data readouts for the next catalyst.
- NEUTRAL EFFECTSep 23, 2026
The SEC declared effective Regentis Biomaterials Ltd.'s registration statement (File No…
The effective registration allows pricing to proceed imminently. Watch for the final pricing announcement and first-day trading performance. The $3.00 assumed price is the reference point; any…
- BULLISH 6-KJul 20, 2026
Regentis received a Japanese patent allowance for its proprietary organic solvent-free…
The patent allowance is a modest positive catalyst that reinforces GelrinC's competitive moat in Japan. Traders should watch for updates on European commercial launch timing and U.S. trial…
- BULLISH 6-KJul 15, 2026
Regentis received European Notified Body approval for a next-generation solvent-free manufacturing…
This regulatory approval removes a key manufacturing bottleneck ahead of European commercialization, significantly improving the unit economics and supply potential for GelrinC. Traders should…
All RGNT filing & press-release reports (8)
- 6-K reportOct 13, 2026
- EFFECT reportSep 23, 2026
- 6-K reportJul 20, 2026
- 6-K reportJul 15, 2026
- EFFECT reportJul 14, 2026
- 6-K reportJun 15, 2026
- F-1/A reportJun 9, 2026
- 6-K reportJun 8, 2026